mosunetuzumab

INN (International Nonproprietary Name)

🇺🇸 Also approved in the US (FDA)

LUNSUMIO — GENENTECH INC, approved 2026-06-18 (BLA761263).

Most reported adverse events (US / FAERS)

891 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

cytokine release syndrome

180

disease progression

114

neutropenia

80

covid-19

67

Medicines containing this active substance

1 medicines

Lunsumio

Authorised

🇺🇸 Also approved in the US (FDA)

LUNSUMIO — GENENTECH INC, approved 2026-06-18 (BLA761263).

Most reported adverse events (US / FAERS)

891 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

cytokine release syndrome

180

disease progression

114

neutropenia

80

covid-19

67

off label use

63

pyrexia

59

death

47

pneumonia

47

malignant neoplasm progression

45

covid-19 pneumonia

40

disorientation

31

neurological symptom

31

vasogenic cerebral oedema

31

diffuse large b-cell lymphoma recurrent

28

rash

28